Melarsomine Dihydrochloride,Glycerin

Verify with FDA CVM →

17 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
17
Total Reports
0
Deaths Reported
0.0%
Death Rate

Active Ingredients

Melarsomine Dihydrochloride,Glycerin

Administration Routes

UnknownIntramuscularParenteralTopicalVaginal

Species Affected

Dog 17

Most Affected Breeds

Retriever - Labrador 4
Chihuahua 3
Siberian Husky 2
Pit Bull 1
Shepherd Dog - German 1
Mountain Cur 1
Boxer (German Boxer) 1
Poodle - Standard 1
Cattle Dog - Australian (blue heeler, red heeler, Queensland cattledog) 1
Collie - Border 1

Most Reported Reactions

Lack of efficacy (endoparasite) - heartworm 15
Diarrhoea 1
Decreased appetite 1
Sleepiness - systemic disorder 1
Cough 1
Sickness 1
Elevated liver enzymes 1
Ocular discharge 1
Lethargy (see also Central nervous system depression in Neurological) 1
Facial swelling (see also Skin) 1
Reddening of the skin 1
Periorbital oedema 1

Outcome Breakdown

Outcome Unknown
14 (82.4%)
Recovered/Normal
3 (17.6%)

Data Summary

Metric Value
Total adverse event reports 17
Reports involving death 0
Case-fatality rate (reported events) 0.0%
Distinct species in reports 1
Distinct breeds in reports 11
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Melarsomine Dihydrochloride,Glycerin Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 17 adverse event reports referencing Melarsomine Dihydrochloride,Glycerin, including 0 reports in which the animal died — a 0.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Melarsomine Dihydrochloride,Glycerin. Reported administration routes include Unknown, Intramuscular, Parenteral, Topical. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Melarsomine Dihydrochloride,Glycerin reports are Dog (17 reports), with Dog accounting for the largest share. Within those species, Retriever - Labrador (4), Chihuahua (3), Siberian Husky (2) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Melarsomine Dihydrochloride,Glycerin are Lack of efficacy (endoparasite) - heartworm (15), Diarrhoea (1), Decreased appetite (1), Sleepiness - systemic disorder (1). Of the 17 reports with a coded outcome, Outcome Unknown is the leading category at 82.4%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Melarsomine Dihydrochloride,Glycerin.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial